Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 726 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological... July 16, 2021 How CRISPR is Changing Cancer Research and Treatment July 27, 2020 Load more HOT NEWS 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... New insights on self-sampling for cervical cancer screening Atlantic rowing trio smash world record and raise thousands for cancer... News digest – ovarian cancer blood test, statins, spending review and...
